CD8A and type 1 diabetes mellitus: Considering that AREG can restrain the antiviral activity of CD8+T cells in hepatitis B (38) we can suppose that its reduction could eventually be protective against virus infection, the potential candidate in T1D pathogenesis (36, 39, 40).